Clinical trials: Advanced RCC
Kidney Cancer
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00003102
- Testing
- Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Ludwig Institute for Cancer Research
Advanced Renal Cell Carcinoma
Clinical Study of a Novel Humanized CD70-Targeted CAR-T Cell Incorporating TLR2 for Advanced Renal Cell Carcinoma Therapy
In this clinical study, participants with advanced renal cell carcinoma will receive a novel humanized CD70-targeted CAR-T-cell product that incorporates the TLR2 co-stimulatory domain.
- Trial name
- NCT07113977
- Testing
- CAR-T(CD70)
- Volunteers
- 30 people
- Sponsor
- Wei Guan
Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
TITAN RCC (0216-ASG) is a Phase 2, open-label study of nivolumab monotherapy with additional nivolumab/ipilimumab "boost" cycles in previously untreated and pretreated (2nd line), advanced or metastatic renal cell carcinoma…
- Trial name
- TITAN-RCC (NCT02917772)
- Testing
- Nivolumab/Ipilimumab
- Where
- 35 sites in Austria, Belgium and 6 more
- Volunteers
- 200 people
- Sponsor
- AIO-Studien-gGmbH
Metastatic Renal Cell Carcinoma
Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control
This study aims to assess the survival benefit from an early switch approach from sunitinib or pazopanib (10-12 weeks of 1st-line therapy) to nivolumab (anti-angiogenic to immunotherapy switch).
- Trial name
- NIVOSWITCH (NCT02959554)
- Testing
- Nivolumab, Sunitinib, Pazopanib
- Where
- 2 sites in Austria, Germany
- Volunteers
- 49 people
- Sponsor
- AIO-Studien-gGmbH
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma
- Trial name
- NCT05783622
- Testing
- JANX008
- Where
- 18 sites in United States
- Volunteers
- 130 people
- Sponsor
- Janux Therapeutics
Papillary Renal Cell Carcinoma
Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma
Multicenter, single arm, phase II study using a A'Hern single-stage procedure in patients with locally advanced or metastatic papillary renal cell carcinoma (PRCC) in first-line treatment.
- Trial name
- AXIPAP (NCT02489695)
- Testing
- Axitinib
- Where
- 10 sites in France
- Volunteers
- 44 people
- Sponsor
- Centre Leon Berard
Breast Neoplasms, Ovarian Neoplasms
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
The primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers.
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms
- Trial name
- NCT00120939
- Testing
- Motexafin Gadolinium
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Pharmacyclics LLC.
RCC, Renal Cell Cancer
Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy
The primary objective is to evaluate the improvement in Objective Response Rate (ORR) achieved with Iparomlimab and Tuvonralimab Injection (QL1706, an Anti-PD-1/CTLA-4 Combined Antibody) in combination with Lenvatinib or…
- Trial name
- NCT07277972
- Testing
- Iparomlimab and Tuvonralimab Injection in combination with Lenvatinib or Axitinib
- Volunteers
- 36 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer, Ovarian Cancer
A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing
The purpose of this study is to evaluate the feasibility, safety, and tolerability of administering ZYC300 with Cyclophosphamide (Cytoxan).
- Conditions
- Breast Cancer, Ovarian Cancer, Prostate Cancer, Colon Cancer
- Trial name
- NCT00381173
- Testing
- Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Eisai Inc.
Solid Tumor, Renal Cell Cancer Metastatic
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with…
- Conditions
- Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT04903873
- Testing
- EU101
- Where
- 6 sites in United States, South Korea
- Volunteers
- 110 people
- Sponsor
- Eutilex
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer
This phase II trial is studying how well ixabepilone works in treating patients with metastatic, recurrent, or unresectable kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00182702
- Testing
- ixabepilone, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Tumor, Advanced Solid Tumor
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
- Conditions
- Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
- Trial name
- NCT05420545
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT00004065
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Renal Cell Carcinoma
Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
CMN-001 is an autologous, tumor antigen-loaded dendritic cell immunotherapy. The active components of CMN-001 are autologous, matured dendritic cells, which have been co-electroporated with both in vitro transcribed (IVT) RNA…
- Trial name
- NCT04203901
- Testing
- CMN-001, Nivolumab+Ipilimumab, Lenvatinib+Everolimus
- Where
- 9 sites in United States
- Volunteers
- 16 people
- Sponsor
- CoImmune
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Advanced or Metastatic Renal Cell Carcinoma
Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)
The purpose of this study is to describe the real-life use of Cabometyx® in monotherapy or in combination with nivolumab in Belgium in patients with advanced or metastatic Renal Cell Carcinoma (1st, 2nd and later lines of…
- Trial name
- REPLICA (NCT04106349)
- Where
- 20 sites in Belgium
- Volunteers
- 150 people
- Sponsor
- Ipsen
Renal Cell Carcinoma
Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma
This study investigates the safety and efficacy of sodium pentaborate pentahydrate in patients with advanced renal cell carcinoma.
- Trial name
- NCT05798455
- Testing
- Sodium Pentaborate
- Where
- Iran
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tabriz University of Medical Sciences
Colorectal Cancer, Non-Small Cell Lung Cancer
Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment
A multi-center, open-label, extended treatment, clinical trial examining the safety of administering multiple does of panitumumab by intravenous (i.v.) infusion to patients who have previously received panitumumab and benefited…
- Conditions
- Colorectal Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Solid Tumors
- Trial name
- NCT00425204
- Testing
- Panitumumab (ABX-EGF)
- Volunteers
- 31 people
- Sponsor
- Amgen
Advanced Renal Cell Carcinoma
Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma
This is a study to evaluate the safety, efficacy and pharmacokinetics of temsirolimus in Asian patients with advanced renal cell carcinoma. The trial is only being conducted in Japan, Korea, and China.
- Trial name
- NCT00494091
- Testing
- Temsirolimus (CCI-779)
- Where
- 24 sites in China, Japan and 1 more
- Volunteers
- 82 people
- Sponsor
- Pfizer
Advanced Renal Cell Carcinoma
An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK
An observational chart review study to describe the real-world outcomes and use of avelumab in combination with axitinib for treatment of patients with advanced renal cell carcinoma in the United Kingdom.
- Trial name
- NCT05394493
- Testing
- avelumab, axitinib
- Where
- United Kingdom
- Volunteers
- 130 people
- Sponsor
- Pfizer